You are here

Nefazodone HCl Approved by FDA

CORONA, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that it has received final approval from the United States Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for nefazodone hydrochloride tablets in the 100 mg, 150 mg, 200 mg and 250 mg strengths. Nefazodone hydrochloride is the generic equivalent of Bristol-Myers Squibb's Serzone® and is indicated for the treatment of depression. For the 12-months ending June 2003, Serzone® had sales of approximately $220 million for all strengths, according to IMS data. Watson's nefazodone hydrochloride product will be launched immediately, making it the Company's 21st product launched in 2003.

Source: Watson Pharmaceuticals, Inc.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug